期刊论文详细信息
Journal of Pharmacological Sciences
Usefulness of CD4+CD45RBhigh CD25− Cell–Transferred SCID Mice for Preclinical Evaluation of Drugs for Inflammatory Bowel Disease
Daisuke Hirano1  Shihoko Kudo2 
[1] Research and Development Division, Perseus Proteomics, Inc., Japan;UMN Pharma, Inc., Exploratory Research Division Molecular Medicine Laboratory, Bioscience Education and Research Center, Akita University, Japan
关键词: inflammatory bowel disease;    experimental model;    SCID mice;    corticosteroid;    anti-tumor necrosis factor (TNF)-α antibody;   
DOI  :  10.1254/jphs.08293FP
学科分类:药学
来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society
PDF
【 摘 要 】

References(31)Cited-By(6)Mouse colitis induced by transfer of CD4+CD45RBhigh CD25− cells share many pathological features with human inflammatory bowel disease (IBD). However, there is little known about how mouse colitis responds to drugs used for IBD treatment. To address this issue, we have investigated the effects of the IBD drugs, dexamethasone and anti-tumor necrosis factor-α antibody, on the mouse experimental colitis. Administration of either drug ameliorated their morbid signs such as body weight loss, colon shortening, and an increased ratio between colon and body weights (C/B ratio). Also improved were mucosal inflammatory signs in the colon, and histological damage scores were significantly decreased. Of the proinflammatory cytokines assayed in colon and plasma samples from the colitis mice, the colonic interleukin (IL)-1β level alone was significantly decreased by either drug administration. Regression analysis of data obtained with either drug revealed a close correlation between the histological damage score and C/B ratio or colonic IL-1β level. The present results show that the experimental mouse colitis responds to IBD drugs with its amelioration and that the C/B ratio and colonic IL-1β are available as a disease marker for IBD, suggesting the usefulness of this mouse model of colitis for pre-clinical screening of drug candidates for IBD treatment.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201911300219716ZK.pdf 1063KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:1次